Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results – Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 – — Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at approximately 42.0% — — Company to host conference call today at 8:00 a.m. Eastern Time — SOUTH SAN FRANCISCO, C ...

Twist Bioscience (TWST) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of busi ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Whi ...

Financial Data and Key Metrics Changes - Revenue for the second quarter increased to $75.3 million, representing a 25% year-over-year growth and approximately 5% sequentially [44] - Gross margin for the second quarter came in higher than expected at 41%, with a significant contribution from Express Genes and NGS [44][50] - The company anticipates gross margin to exceed 50% by the end of fiscal 2025 [42][31] Business Line Data and Key Metrics Changes - SynBio revenue increased to $29.8 million, growing 24% year-over-year, with orders rising to $44.9 million [45] - NGS revenue grew to approximately $40.8 million, a 40% increase year-over-year, with orders increasing to $42.5 million [46] - Biopharma revenue was $4.7 million, with orders increasing to $5.8 million [41] Market Data and Key Metrics Changes - Healthcare revenue rose to $40.9 million, reflecting increased uptake by pharma, biotech, and diagnostic companies [48] - Industrial chemical revenue increased to $20.3 million, up from $14.4 million year-over-year [48] - Academic revenue was $13.7 million, up from $11.1 million, driven by growth in both SynBio and NGS customers [48] Company Strategy and Development Direction - The company is focused on expanding its synthetic biology, NGS, biopharma, and data storage segments, leveraging its proprietary DNA synthesis platform [62] - A marketing campaign for Express Gene was launched to attract customers from competitors, with a goal to capture a larger market share [32] - The company is negotiating contracts with suppliers and customers to provide volume commitments and fixed premium pricing, which is expected to enhance margins [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market potential for liquid biopsy applications, indicating significant growth opportunities [68] - The company noted that the increase in blanket purchase orders reflects customer confidence in their offerings, particularly Express Genes [71] - Management highlighted the importance of maintaining financial discipline and the path to profitability, with expectations for improved adjusted EBITDA in future quarters [54][58] Other Important Information - The company shipped to 2,253 customers during the second quarter and ended with approximately $292 million in cash and short-term investments [44] - Operating expenses for the second quarter were $124.2 million, with a net loss attributable to common stockholders of $45.5 million [57] Q&A Session Summary Question: Can you provide insights on the customer feedback regarding dynamic pricing? - Management indicated that there has been no negative feedback on premium pricing, with customers willing to provide volume commitments in exchange for fixed pricing [1] Question: What is the profile of the 100 net new accounts for Express Gene? - The new accounts are a mix of large and small pharma customers, with a significant number being academic groups [5] Question: How is the onboarding of new business development hires progressing? - Management confirmed that the team is in place, and while not fully ramped, they are optimistic about market opportunities and growth potential [10] Question: What are the expectations for Express Gene's contribution to margins? - Management noted that while Express Gene's contribution is still early, it is expected to positively impact gross margins as the year progresses [65] Question: Were there any one-time factors affecting the order trends this quarter? - Management clarified that the increase in orders was driven by a higher number of blanket purchase orders, reflecting customer confidence in their offerings [71]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Exhibit 99.1 Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results – Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 – – Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 – — Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% — — Company to host conference call today at 4:30 p.m. Eastern Time — SOUTH SAN FRANCISCO, Calif. -- (May 2, 2024) — Twist Bioscience C ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 in Boston, ...

Yuichiro Chino/Moment via Getty Images Twist Bioscience (NASDAQ:TWST) recently reported strong results in Q1 FY2024, particularly given how tepid the demand environment is. While some of this strength is a mirage created by lumpy NGS revenue, Twist's business continues to scale and progress towards cash flow breakeven. The stock may not look particularly cheap given its rise over the past 3 months, but it should be kept in mind that both the Biopharma and Data Storage businesses have significant potenti ...

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. “ Element continues to expand its customer base, brin ...

Twist Bioscience Corporation (NASDAQ:TWST) Q1 2024 Earnings Conference Call February 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Steven Mah - Cowen Vijay Kumar - Evercore ISI Luke Sergott - Barclays Matt Larew - William Blair Catherine Schulte - Baird Puneet Souda - Leerink Partners Sung-Ji Nam - Scotiabank ...